文献速递胸部肿瘤支持与姑息治疗

恶性间皮瘤患者癌症易感基因胚系突变频率研究

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.
PubMed 文献 · J Clin Oncol · 2018-08-16

该研究对198例胸膜、腹膜及睾丸鞘膜恶性间皮瘤患者进行85个癌症易感基因的胚系DNA靶向捕获测序,发现23例(12%)携带胚系突变,BAP1最常见(6例,25%)。腹膜部位、石棉暴露少、年轻及第二原发癌与胚系突变风险升高相关,支持对间皮瘤患者开展临床胚系基因检测。

要点

  • 12%(23/198)的恶性间皮瘤患者携带癌症易感基因胚系突变,BAP1突变最常见。
  • 腹膜间皮瘤、石棉暴露少、年轻及第二原发癌患者携带胚系突变的几率更高。
  • 肿瘤测序中52%(29/54)检出同源重组通路基因突变,提示该通路值得进一步研究。

核心结论

  • 相当比例的恶性间皮瘤患者携带癌症易感基因胚系突变,尤其见于腹膜间皮瘤、石棉暴露少、年轻及有第二原发癌诊断的患者。
  • 数据支持对恶性间皮瘤患者开展临床胚系基因检测,并为间皮瘤同源重组通路的进一步研究提供依据。

研究设计与样本

  • 对198例胸膜、腹膜及睾丸鞘膜恶性间皮瘤患者的胚系DNA进行85个癌症易感基因的靶向捕获与下一代测序。

主要发现

  • 198例患者中23例(12%)在13个基因中检出24个胚系突变,BAP1突变最常见(n=6,25%)。
  • 其余突变分布于DNA损伤感知与修复基因(n=14)、氧感知基因(n=2)、内体运输基因(n=1)和细胞生长基因(n=1)。
  • 胸膜部位(OR 0.23,95%CI 0.10-0.58,P<.01)、石棉暴露(OR 0.28,95%CI 0.11-0.72,P<.01)和年龄较大(OR 0.95,95%CI 0.92-0.99,P=.01)与携带胚系突变的几率降低相关。
  • 第二原发癌诊断(OR 3.33,95%CI 1.22-9.07,P=.02)显著增加携带胚系突变的几率。
  • 与无癌对照人群相比,间皮瘤患者携带BAP1(OR 1658,95%CI 199-76224,P<.001)、BRCA2(OR 5,95%CI 1.0-14.7,P=.03)、CDKN2A(OR 53,95%CI 6-249,P<.001)、TMEM127(OR 88,95%CI 1.7-1105,P=.01)、VHL(OR 51,95%CI 1.1-453,P=.02)和WT1(OR 20,95%CI 0.5-135,P=.049)突变的几率显著更高。

临床怎么用

  • 对恶性间皮瘤患者,尤其腹膜间皮瘤、石棉暴露少、年轻及有第二原发癌诊断者,应考虑临床胚系基因检测。
  • 检测可涵盖BAP1、BRCA2、CDKN2A、TMEM127、VHL、WT1等癌症易感基因。
  • 肿瘤同源重组通路突变高发提示可探索相关靶向或免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of the current study was to determine the prevalence and clinical predictors of germline cancer susceptibility mutations in patients with malignant mesothelioma (MM). METHODS: We performed targeted capture and next-generation sequencing of 85 cancer susceptibility genes on germline DNA from 198 patients with pleural, peritoneal, and tunica vaginalis MM. RESULTS: Twenty-four germline mutations were identified in 13 genes in 23 (12%) of 198 patients. BAP1 mutations were the most common (n = 6; 25%). The remaining were in genes involved in DNA damage sensing and repair (n = 14), oxygen sensing (n = 2), endosome trafficking (n = 1), and cell growth (n = 1). Pleural site (odds ratio [OR], 0.23; 95% CI, 0.10 to 0.58; P < .01), asbestos exposure (OR, 0.28; 95% CI, 0.11 to 0.72; P < .01), and older age (OR, 0.95; 95% CI, 0.92 to 0.99; P = .01) were associated with decreased odds of carrying a germline mutation, whereas having a second cancer diagnosis (OR, 3.33; 95% CI, 1.22 to 9.07; P = .02) significantly increased the odds. The odds of carrying a mutation in BAP1 (OR, 1,658; 95% CI, 199 to 76,224; P < .001), BRCA2 (OR, 5; 95% CI, 1.0 to 14.7; P = .03), CDKN2A (OR, 53; 95% CI, 6 to 249; P < .001), TMEM127 (OR, 88; 95% CI, 1.7 to 1,105; P = .01), VHL (OR, 51; 95% CI, 1.1 to 453; P = .02), and WT1 (OR, 20; 95% CI, 0.5 to 135; P = .049) were significantly higher in MM cases than in a noncancer control population. Tumor sequencing identified mutations in a homologous recombination pathway gene in 52% (n = 29 of 54). CONCLUSION: A significant proportion of patients with MM carry germline mutations in cancer susceptibility genes, especially those with peritoneal MM, minimal asbestos exposure, young age, and a second cancer diagnosis. These data support clinical germline genetic testing for patients with MM and provide a rationale for additional investigation of the homologous recombination pathway in MM.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Panou V, Gadiraju M, Wolin A, et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018. PMID: 30113886. doi:10.1200/JCO.2018.78.5204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。